Compare · LLY vs NATR
LLY vs NATR
Side-by-side comparison of Eli Lilly and Company (LLY) and Nature's Sunshine Products Inc. (NATR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and NATR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.08T, about 3114.5x NATR ($347.5M).
- Over the past year, LLY is up 48.6% and NATR is up 36.4% - LLY leads by 12.2 points.
- Both names hit the wire about 17 times in the past 4 weeks.
- LLY has more recent analyst coverage (25 ratings vs 5 for NATR).
- Company
- Eli Lilly and Company
- Nature's Sunshine Products Inc.
- Price
- $1149.79+1.50%
- $19.86+0.35%
- Market cap
- $1.08T
- $347.5M
- 1M return
- +17.88%
- -18.86%
- 1Y return
- +48.64%
- +36.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 17
- 17
- Recent ratings
- 25
- 5
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Nature's Sunshine Products Inc.
Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. It also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. The company offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is based in Lehi, Utah.
Latest LLY
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
Latest NATR
- EVP & President, Asia Norman Daniel C sold $200,476 worth of shares (9,713 units at $20.64), decreasing direct ownership by 17% to 47,276 units (SEC Form 4)
- EVP, General Counsel Brower Nathan G sold $262,408 worth of shares (12,015 units at $21.84), decreasing direct ownership by 22% to 43,438 units (SEC Form 4)
- Director Fasching Steven J. was granted 4,500 shares, increasing direct ownership by 41% to 15,369 units (SEC Form 4)
- Director Wissmiller Heidi was granted 4,500 shares, increasing direct ownership by 12% to 41,667 units (SEC Form 4)
- EVP & President, Europe Yates Bryant J was granted 8,753 shares, increasing direct ownership by 11% to 89,414 units (SEC Form 4)
- EVP, Global Supply Chain Fritz Erich A was granted 9,226 shares, increasing direct ownership by 79% to 20,889 units (SEC Form 4)
- Director May Katie was granted 4,500 shares, increasing direct ownership by 46% to 14,266 units (SEC Form 4)
- EVP, General Counsel Brower Nathan G was granted 9,001 shares, increasing direct ownership by 19% to 55,453 units (SEC Form 4)
- Chief Executive Officer Romanzi Kenneth G. was granted 33,753 shares, increasing direct ownership by 31% to 143,999 units (SEC Form 4)
- SVP, Chief Accounting Officer Lanoy Jonathan David was granted 6,107 shares, increasing direct ownership by 14% to 48,392 units (SEC Form 4)